Related Experiment Video
Updated: Jun 9, 2025
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
Published on: December 17, 2019
Emerging CART Therapies for Pediatric Acute Myeloid Leukemia
Valeria Ceolin1, Manuela Spadea1,2, Vincenzo Apolito1
1Department of Pediatric Oncology/Hematology, Regina Margherita Children's Hospital.
Insights
Chimeric antigen receptor (CAR)-T cell therapy shows promise for pediatric acute myeloid leukemia (AML), especially for relapsed or refractory cases. Identifying specific AML targets remains a key challenge for effective treatment.
Area of Science:
- Pediatric Hematology Oncology
- Immunotherapy
- Cellular Therapy
Background:
- Prognosis for pediatric acute myeloid leukemia (AML) has improved, but outcomes at relapse, particularly for chemorefractory disease, remain poor with overall survival (OS) of 40-50%.
- There is an urgent need for effective, less-toxic therapies for children with relapsed or refractory AML.
- Immune-directed therapies, like chimeric antigen receptor (CAR)-T cells, have demonstrated significant clinical activity in B-cell malignancies.
Purpose of the Study:
- To provide an overview of the prospects of CAR-T cell therapy in pediatric acute myeloid leukemia (AML).
- To focus on common target antigens for CAR-T cell therapy in AML that are currently under investigation or have been tested.
- To discuss the challenges and potential of CAR-T cell therapy for improving outcomes in pediatric AML.
Main Methods:
- Review of current literature on CAR-T cell therapy in hematologic malignancies.
- Analysis of identified target antigens for CAR-T cell therapy in AML.
- Discussion of clinical trial data and ongoing research in pediatric AML immunotherapy.
Main Results:
- CAR-T cell therapy is being developed for AML, building on successes in other hematologic cancers.
- A major challenge in CAR-T therapy for AML is identifying specific target antigens not expressed on healthy hematopoietic stem cells.
- Several common antigens targeted by CAR-T cells in AML are under investigation.
Conclusions:
- CAR-T cell therapy holds significant potential for treating pediatric AML, especially in cases of relapse or refractory disease.
- Overcoming the challenge of target antigen specificity is crucial for the successful and safe application of CAR-T therapy in pediatric AML.
- Further research and clinical investigation are necessary to optimize CAR-T cell therapy for pediatric AML patients.
Abstract:
The prognosis of children with acute myeloid leukemia (AML) has improved incrementally over the last decades. However, at relapse, overall survival (OS) ∼40% to 50% and is even lower for patients with chemorefractory disease. Effective and less-toxic therapies are urgently needed for these children. In the last years, immune-directed therapies such as chimeric antigen receptor (CAR)-T cells were introduced, which showed outstanding clinical activity against B-cell malignancies. CART therapies are being developed for AML on the basis of the results obtained for other hematologic malignancies. The biggest challenge of CART therapy for AML is to identify a specific target antigen, since antigens expressed in AML cells are usually shared with healthy hematopoietic stem cells. An overview of prospects of CART in pediatric AML, focused on the common antigens targeted by CART in AML that have been tested or are currently under investigation, is provided in this manuscript.
More Related Videos
09:56A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
Published on: February 21, 2025
05:22Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice
Published on: February 24, 2023
